The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Nippon Shinyaku Co Ltd (Nippon Shinyaku) develops, manufactures, and commercializes prescribed pharmaceuticals and functional foods. The company offers products for pain, inflammation, and allergies; urological diseases; hematologic malignancies; gastrointestinal disorders; cardiovascular and metabolic diseases, among others. The company produces functional foods and ingredients, including preservatives, health food ingredients, and protein preparations. Its functional food products find application in meat processing, fish processing, dairy products, prepared food, confectionery and bakery, and beverage, among others. The company operates business through a network of offices and research laboratories located in Japan, China, the UK, and the US. Nippon Shinyaku is headquartered in Minami-ku, Kyoto, Japan.Nippon Shinyaku Co Ltd Key Recent Developments
- Aug 26, 2026: Japan Novartis Co., Ltd. Announces Innovative Drug Designation for NS-035 for Fukuyama Congenital Muscular Dystrophy
- Aug 17, 2026: Japan New Pharmaceutical Co., Ltd. Relocates Kobe and Hanshin Sales Offices
- Aug 06, 2026: Consolidated Financial Results for the First Quarter of Fiscal Year 2026 (IFRS) — NIPPON SHINYAKU CO., LTD.
- Jul 01, 2026: Nippon Shinyaku Selected as a Constituent of the SOMPO Sustainability Index
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Kyowa Kirin Co Ltd
- Taisho Pharmaceutical Holdings Co Ltd
- Mochida Pharmaceutical Co Ltd
- Astellas Pharma Inc
- Shionogi & Co Ltd
- Senju Pharmaceutical Co Ltd
- Incyte Corp
- ASKA Pharmaceutical Holdings Co Ltd

